Andrea Nemcova

Andrea Nemcova

Auto-generated profile, based on publicly available information

Andrea Nemcova

Diabetes Centre, Institute for Clinical and Experimental Medicine, 14021 Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DSDominika Sojakova
Dominika Sojakova
JHJitka Husakova
Jitka Husakova
VFVladimira Fejfarova
Vladimira Fejfarova
ANAndrea Nemcova
Andrea Nemcova
RJRadka Jarosikova
Radka Jarosikova
MDMichal Dubsky
Michal Dubsky
Autologous cell therapy (ACT) is primarily used in diabetic patients with chronic limb-threatening ischemia (CLTI) who are not candidates for standard revascularization. According to current research, this therapy has been shown in some studies to be effective in improving ischemia parameters, decreasing the major amputation rate, and in foot ulcer healing. This review critically evaluates the efficacy of ACT in patients with no-option CLTI, discusses the use of mononuclear and mesenchymal stem cells, and compares the route of delivery of ACT. In addition to ACT, we also describe the use of new revascularization strategies, e.g., nanodiscs, microbeads, and epigenetics, that could enhance the therapeutic effect. The main aim is to summarize new findings on subcellular and molecular levels with the clinical aspects of ACT.